PITTSBURGH , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), a gene therapy company developing medicines to treat rare diseases, today announced the appointment of Jennifer Chien to the newly created position of chief commercial officer, effective January 20, 2020. Ms.

PITTSBURGH , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S.

Alignment With FDA on GMP Commercial Manufacturing Process for KB103 (Bercolagene telserpavec, “B-VEC”) KB105 Granted Fast Track Designation by the FDA Platform Patent for Delivering any Effector to the Skin Granted by USPTO PITTSBURGH , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc.

Safety data from all patients (Phase 1 and Phase 2) show that B-VEC was well tolerated with no related adverse events reported. Nine out of 10 of the wounds closed completely (100% closure) following initial administrations of B-VEC. The average time to wound closure was 17.4 days.

PITTSBURGH , Oct. 10, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive

PITTSBURGH , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S.

PITTSBURGH , Sept. 27, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, announced the granting of a new patent for its lead product candidate

PITTSBURGH , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced the initiation of the Phase 1/2 study of KB105 in transglutaminase-1 (TGM1) deficient autosomal recessive

PITTSBURGH , Aug. 27, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S.

FDA grants RMAT designation for KB103 to treat dystrophic epidermolysis bullosa (DEB) Announced positive results from Phase 2 trial (“GEM-2”) of KB103 Submitted an IND application to initiate a Phase 1/2, first in-human trial of KB105 to treat patients with TGM1-deficient autosomal recessive